Most Compact System for Early Stage Processes – The Eppendorf DASbox Mini Bioreactor System, with its small working volume, compact design, as well as advanced control and information management options is ideal for research and early development processes.
Evotec expanding at Milton Park campus
Latest NewsEvotec SE is set to expand the company’s existing campus in Milton Park/Abingdon, UK, into a major, fully-integrated drug discovery and development centre.
Pfizer/BioNTech sign vaccine contract with EC
Latest NewsPfizer and Biontech SE have reached an agreement with the European Commission to supply 200 million doses of their mRNA-based COVID-19 vaccine candidate.
1,800+ experts will join the Global Bioeconomy Summit
Latest NewsMore than 1,800 attendees already registered for the Global Bioeconomy Summit 2020. The conference takes place virtually from November 16 to 20.
BioNTech reports high efficacy of COVID-19 vaccine
Latest NewsInterim data on BioNtechs/Pfizers COVID-19 vaccine candidate BNT162b2 suggest an efficacy of more than 90% – 30% better than required by the FDA.
Vifor Pharma inks $340m deal with Angion Biomedica Inc.
Latest NewsSwiss drugmaker Vifor Pharma has licenced US and EU commercialisation rights of Angion Biomedicas experimental kidney drug ANG-3777.
DASbox® Mini Bioreactor System
ProductsMost Compact System for Early Stage Processes – The Eppendorf DASbox Mini Bioreactor System, with its small working volume, compact design, as well as advanced control and information management options is ideal for research and early development processes.
New Director General of EuropaBio
AppointmentsClaire Skentelbery, well known and connected in the European biotech community, will be the new Director General of EuropaBio. She will join the EuropaBio team at the end of November.
ELRIG keeping connected
AppointmentsMelanie Leveridge takes over the lead of the European Laboratory Research & Innovation Group (ELRIG) UK to drive further collaboration between academia and biopharma industry.
Richter-Helm, the CDMO matching your needs
Sponsored PublicationsCDMO Continuous growth and diversification of the biotechnology market for pharmaceutical production have been recorded in the past years. It is expected that both trends, growth and diversification from blockbusters towards niche products, will continue. What requirements are derived from customers’ point of view and what are the advantages of Richter-Helm as a successful CDMO to fulfil such needs?
Whats in a patent?
BackgroundIP – In a recent decision (Royalty vs. DPMA; C-650/17), the European Court of Justice (ECJ) has shed some light on the conditions under which a supplementary protection certificate (SPC) may be granted. It has thus ended discussions that had arisen following earlier somewhat elusive ECJ-decisions. Whether this will be the last word to be heard on the topic remains to be seen.